JP2021526505A5 - - Google Patents

Info

Publication number
JP2021526505A5
JP2021526505A5 JP2020558508A JP2020558508A JP2021526505A5 JP 2021526505 A5 JP2021526505 A5 JP 2021526505A5 JP 2020558508 A JP2020558508 A JP 2020558508A JP 2020558508 A JP2020558508 A JP 2020558508A JP 2021526505 A5 JP2021526505 A5 JP 2021526505A5
Authority
JP
Japan
Prior art keywords
lnp
lnp preparation
preparation according
mol
therapeutic protein
Prior art date
Application number
JP2020558508A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019204666A5 (https=
JP2021526505A (ja
JP7592493B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/028207 external-priority patent/WO2019204666A1/en
Publication of JP2021526505A publication Critical patent/JP2021526505A/ja
Publication of JP2021526505A5 publication Critical patent/JP2021526505A5/ja
Publication of JPWO2019204666A5 publication Critical patent/JPWO2019204666A5/ja
Priority to JP2024060375A priority Critical patent/JP2024105237A/ja
Application granted granted Critical
Publication of JP7592493B2 publication Critical patent/JP7592493B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020558508A 2018-04-18 2019-04-18 治療用タンパク質の標的細胞に特異的な産生のための、および、標的細胞に関連する疾患、疾病、または障害の処置のための、融合性脂質ナノ粒子、および、融合性脂質ナノ粒子の製造方法と使用方法 Active JP7592493B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024060375A JP2024105237A (ja) 2018-04-18 2024-04-03 治療用タンパク質の標的細胞に特異的な産生のための、および、標的細胞に関連する疾患、疾病、または障害の処置のための、融合性脂質ナノ粒子、および、融合性脂質ナノ粒子の製造方法と使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862659676P 2018-04-18 2018-04-18
US62/659,676 2018-04-18
US201962821084P 2019-03-20 2019-03-20
US62/821,084 2019-03-20
PCT/US2019/028207 WO2019204666A1 (en) 2018-04-18 2019-04-18 Fusogenic lipid nanoparticles and methods for the manufacture and use thereof for the target cell-specific production of a therapeutic protein and for the treatment of a disease, condition, or disorder associated with a target cell

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024060375A Division JP2024105237A (ja) 2018-04-18 2024-04-03 治療用タンパク質の標的細胞に特異的な産生のための、および、標的細胞に関連する疾患、疾病、または障害の処置のための、融合性脂質ナノ粒子、および、融合性脂質ナノ粒子の製造方法と使用方法

Publications (4)

Publication Number Publication Date
JP2021526505A JP2021526505A (ja) 2021-10-07
JP2021526505A5 true JP2021526505A5 (https=) 2022-05-30
JPWO2019204666A5 JPWO2019204666A5 (https=) 2022-05-30
JP7592493B2 JP7592493B2 (ja) 2024-12-02

Family

ID=68239921

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020558508A Active JP7592493B2 (ja) 2018-04-18 2019-04-18 治療用タンパク質の標的細胞に特異的な産生のための、および、標的細胞に関連する疾患、疾病、または障害の処置のための、融合性脂質ナノ粒子、および、融合性脂質ナノ粒子の製造方法と使用方法
JP2024060375A Pending JP2024105237A (ja) 2018-04-18 2024-04-03 治療用タンパク質の標的細胞に特異的な産生のための、および、標的細胞に関連する疾患、疾病、または障害の処置のための、融合性脂質ナノ粒子、および、融合性脂質ナノ粒子の製造方法と使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024060375A Pending JP2024105237A (ja) 2018-04-18 2024-04-03 治療用タンパク質の標的細胞に特異的な産生のための、および、標的細胞に関連する疾患、疾病、または障害の処置のための、融合性脂質ナノ粒子、および、融合性脂質ナノ粒子の製造方法と使用方法

Country Status (6)

Country Link
US (3) US11603543B2 (https=)
EP (1) EP3784252A4 (https=)
JP (2) JP7592493B2 (https=)
CN (2) CN121775163A (https=)
CA (1) CA3097411A1 (https=)
WO (1) WO2019204666A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018206485B2 (en) 2017-01-09 2024-12-05 Oisin Biotechnologies Fusogenic lipid nanoparticles and methods for manufacturing and use for therapeutic protein production and for treatment
WO2019204666A1 (en) 2018-04-18 2019-10-24 Oisin Biotechnologies, Inc. Fusogenic lipid nanoparticles and methods for the manufacture and use thereof for the target cell-specific production of a therapeutic protein and for the treatment of a disease, condition, or disorder associated with a target cell
SG11202105079QA (en) * 2018-11-14 2021-06-29 Flagship Pioneering Innovations V Inc Fusosome compositions for cns delivery
US12496274B2 (en) 2018-11-14 2025-12-16 Flagship Pioneering Innovations V, Inc. Compositions and methods for compartment-specific cargo delivery
CA3094859A1 (en) * 2020-10-01 2022-04-01 Entos Pharmaceuticals Inc. Proteolipid vesicles formulated with fusion associated small transmembrane proteins
CN114540416A (zh) * 2022-02-18 2022-05-27 上海交通大学 一种表达载体、脂质纳米粒、抗肿瘤药物及其制备方法和用途
WO2024036148A1 (en) * 2022-08-08 2024-02-15 A2 Biotherapeutics, Inc. Compositions and methods for treating blood cancers
CN116712406B (zh) * 2023-04-23 2026-03-31 深圳复生命生物医药有限公司 一种病毒样纳米粒子核酸药物递送系统、制备方法及应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69132032T2 (de) 1990-11-23 2000-12-21 Peptech Ltd., North Ryde Verzögerung, verhinderung und/oder rückgängigmachen von zellalterung
US5869337A (en) 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
CA2289702C (en) 1997-05-14 2008-02-19 Inex Pharmaceuticals Corp. High efficiency encapsulation of charged therapeutic agents in lipid vesicles
EP1018560A4 (en) 1997-08-20 2002-10-02 Dnavec Research Inc CANCER TREATMENT VECTORS
AU1137699A (en) 1997-11-07 1999-05-31 Dalhousie University Novel reovirus-derived proteins, nucleic acids encoding same, and uses therefor
US6899870B1 (en) * 1998-03-11 2005-05-31 Board Of Regents, The University Of Texas System Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery
US6403765B1 (en) * 1998-06-16 2002-06-11 Thomas Jefferson University Truncated Apaf-1 and methods of use thereof
CA2352486A1 (en) 1998-11-25 2000-06-02 Genetica, Inc. Methods and reagents for increasing proliferative capacity and preventing replicative senescence
CA2325088A1 (en) * 2000-12-01 2002-06-01 Fusogenix Inc. Novel membrane fusion proteins derived from poikilothermic reovirus
WO2002101076A2 (en) 2001-06-13 2002-12-19 Eastern Virginia Medical School Methods for targeted expression of therapeutic nucleic acid
CN100361710C (zh) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
JPWO2006043354A1 (ja) 2004-10-20 2008-05-22 独立行政法人放射線医学総合研究所 組込型の低線量放射線誘導性ベクター
EP2167688A4 (en) 2007-06-12 2010-07-28 Univ Case Western Reserve TARGETED CELL DEATH
MX2010012473A (es) 2008-05-23 2011-02-23 Siwa Corp Metodos, composiciones y aparato para facilitar la regeneracion.
HUE042177T2 (hu) * 2009-12-01 2019-06-28 Translate Bio Inc Szteroidszármazék mRNS szállítására humán genetikai betegségekben
WO2011146862A1 (en) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Methods for inducing selective apoptosis
WO2012019053A2 (en) * 2010-08-04 2012-02-09 The Ohio State University Methods for impairing the p53/hdm2 auto-regulatory loop in multiple myeloma development using mir-192, mir-194 and mir-215
WO2012040825A1 (en) 2010-09-29 2012-04-05 Innovascreen Inc. Recombinant polypeptides for membrane fusion and uses thereof
PL3586861T3 (pl) * 2011-06-08 2022-05-23 Translate Bio, Inc. Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna
US20140189897A1 (en) 2011-06-21 2014-07-03 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
JP2014532071A (ja) * 2011-10-14 2014-12-04 エスティーシー． ユーエヌエムＳｔｃ．Ｕｎｍ カーゴの経皮送達を含む標的送達用の多孔性ナノ粒子に担持された脂質二重層（プロトセル）及びその方法
US20150064137A1 (en) 2012-04-17 2015-03-05 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9750819B2 (en) * 2012-05-23 2017-09-05 Ohio State Innovation Foundation Lipid nanoparticle compositions and methods of making and methods of using the same
US9687448B2 (en) * 2012-12-07 2017-06-27 Alnylam Pharmaceuticals, Inc. Nucleic acid lipid particle formulations
WO2014153163A1 (en) 2013-03-14 2014-09-25 Dicerna Pharmaceuticals, Inc. Process for formulating an anionic agent
US10130649B2 (en) * 2013-03-15 2018-11-20 Translate Bio, Inc. Synergistic enhancement of the delivery of nucleic acids via blended formulations
KR20180118259A (ko) 2013-03-24 2018-10-30 오이신 바이오테크놀로지스 표적 세포 내에서 치료적 단백질의 표적화된 생산을 위한 시스템 및 방법
CA2966234A1 (en) 2014-12-15 2016-06-23 Bellicum Pharmaceuticals, Inc. Methods for controlled elimination of therapeutic cells
GB201503133D0 (en) 2015-02-24 2015-04-08 Ucl Business Plc And Syncona Partners Llp Chimeric protein
WO2016185481A2 (en) 2015-05-20 2016-11-24 Yeda Research And Development Co. Ltd. Method of targeting senescent cells
AU2018206485B2 (en) * 2017-01-09 2024-12-05 Oisin Biotechnologies Fusogenic lipid nanoparticles and methods for manufacturing and use for therapeutic protein production and for treatment
WO2019204666A1 (en) 2018-04-18 2019-10-24 Oisin Biotechnologies, Inc. Fusogenic lipid nanoparticles and methods for the manufacture and use thereof for the target cell-specific production of a therapeutic protein and for the treatment of a disease, condition, or disorder associated with a target cell
WO2020163408A2 (en) 2019-02-04 2020-08-13 Oisin Biotechnologies, Inc. Fusogenic lipid nanoparticles for the target cell-specific production of rapamycin inducible therapeutic proteins

Similar Documents

Publication Publication Date Title
JP2021526505A5 (https=)
JP6752299B2 (ja) ｍＲＮＡ送達のための脂質ナノ粒子組成物および方法
ES2968649T3 (es) Nanopartículas lipídicas para la administración de ARNm en los pulmones
IL302770A (en) Compositions and methods for stabilization of lipid nanoparticle mrna vaccines
US20240374520A1 (en) Proteolipid vesicles formulated with fusion associated small transmembrane proteins
US20250346925A1 (en) Fusogenic lipid nanoparticles and methods for the manufacture and use thereof for the target cell-specific production of a therapeutic protein and for the treatment of a disease
JPH06510036A (ja) 嚢胞性線維症の治療のための組成物および方法
CN105294859A (zh) 脂蛋白复合物及其制备和用途
RS60181B1 (sr) Terapeutska upotreba morfogenetskih proteina kosti
JP2010248255A6 (ja) 親油性薬物送達ビヒクルおよびその使用方法
US20200197536A1 (en) Porous nanoparticle-supported lipid bilayer delivery of transcriptional gene modulators
JP2020503390A (ja) 治療用タンパク質の標的細胞特異的な産生のため、および標的細胞に関連する疾患、状態、または障害の治療のための、膜融合性脂質ナノ粒子、ならびにその作製および使用のための方法
CN114788876B (zh) 治疗糖尿病的mRNA药物制剂及其制备方法与应用
JP2003530360A (ja) 薬剤送達のためのペプチド複合体
WO2023051701A1 (zh) 抗SARS-CoV-2感染的mRNA、蛋白以及抗SARS-CoV-2感染的疫苗
JP2007526907A (ja) 親油性薬物送達ビヒクルおよびその使用方法
JPWO2019204666A5 (https=)
WO2016058547A1 (zh) 高活性的肿瘤抑制剂及其制法和应用
JP7236446B2 (ja) コア－シェル構造のマイクロ粒子を有効成分として含む血液凝固因子遺伝子発現増加用組成物
KR20220117133A (ko) 양이온성 분자 수송체 및 SARS-CoV-2 mRNA의 이온 복합체를 포함하는 코로나바이러스감염증-19 예방 백신 조성물
US20140039163A1 (en) Cholesterol-dependent cytolysin variant and use thereof in dds
JP2003250549A (ja) Ｎｋ４遺伝子または組換えｎｋ４蛋白質からなる医薬
JP2025529128A (ja) カスパーゼ活性化及び動員ドメイン（ａｓｃ）を有するアポトーシス関連スペック様タンパク質を標的化する組成物及び使用方法
Wang et al. Recombinant human hepatocyte growth factor transfection alleviates hyperkinetic pulmonary artery hypertension in rabbit models
US20260109963A1 (en) Compositions, systems, and methods for reducing adipose tissue